Craig-Hallum Initiates Coverage on Onyx Pharmaceuticals (ONXX) with a Buy
More News related to ONXX
- Notable Mergers and Acquisitions of the Day 11/16: CSCO, MOT, TTMI, ONXX
- Onyx Pharmaceuticals (ONXX) Completes Acquisition of Proteolix
- Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc.
- Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com
- Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
More News related to New Coverage
- Wedbush Starts Omeros (OMER) at Outperform with a $12 Fair Value
- Davenport Starts C&F Financial (CFFI) at Buy, $23.50 Price Target
- JANCO Partners Initiates Coverage on IMAX Corp (IMAX) with a Buy; Upside Margin Leverage, Studios/Exhibitors Win
- Barclays Initiates Coverage on AGCO Corporation (AGCO) with an Equalweight
- Wunderlich Securities Initiates Coverage on EXCO Resources (XCO) with a Buy
Craig-Hallum initiates coverage on Onyx Pharmaceuticals (Nasdaq: ONXX) with a Buy. Price target $35.
To see more analyst ratings on ONXX Click Here.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally.
Related Categories
New CoverageStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
